clinical trial · NCT02981069
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM
The University of Texas Health Science Center at San Antonio·phase4·completed·n = 90
Diabetes Mellitus, Type 2DapagliflozinExenatidePlacebo
brief summary
In this study, the researchers hope to learn about SGLT2 inhibition on EGP (endogenous glucose production) and plasma glucose concentration in diabetic subjects. Researchers will examine diabetes and the role of increased plasma glucagon, decline in plasma insulin, and fall in plasma glucose concentration.
started
Dec 15, 2017
primary completion
Jul 14, 2022
completion
Mar 19, 2023
last updated
Jul 20, 2023
detailed description
This study will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose concentration compared to each agent alone.
official title
Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in Type 2 Diabetes Mellitus (T2DM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol